The angiotensin II type 1 receptor blocker valsartan attenuates graft vasculopathy

Basic Research in Cardiology

Volumn 100, Issue 1, 2005, Pages 84-91

  Yamamoto, Tetsufumi ^a   Sata, Masataka ^a,b   Fukuda, Daiju ^a   Takamoto, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Angiotensin; Arteriosclerosis; Progenitor; Smooth muscle cell; Transplantation

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BASIC FIBROBLAST GROWTH FACTOR; CELL ADHESION MOLECULE; CYTOKINE; DRUG VEHICLE; IMMUNOSUPPRESSIVE AGENT; PLATELET DERIVED GROWTH FACTOR BB; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOSCLEROSIS; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; GRAFT FAILURE; HEART TRANSPLANTATION; MALE; MONONUCLEAR CELL; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RECIPIENT; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; HEART TRANSPLANTATION; MALE; MICE; MICE, INBRED DBA; TETRAZOLES; VALINE;

EID: 11244301010     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00395-004-0489-0     Document Type: Article

References (30)

1. Billingham ME (1987) Cardiac transplant atherosclerosis. Transplant. Proc 19:19-25
2. Billingham ME, Cary NR, Hammond ME, Kemnitz J, Marboe C, McCallister HA, Snovar DC, Winters GL, Zerbe A (1990) A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 9:587-593
3. Caplice NM, Bunch TJ, Stalboerger PG, Wang S, Simper D, Miller DV, Russell SJ, Litzow MR, Edwards WD (2003) Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci USA 100:4754-4759
4. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675
5. Furukawa Y, Matsumori A, Hirozane T, Sasayama S (1996) Angiotensin II receptorant agonist TCV-116 reduces graft coronary artery disease and preserves graft status in a murine model. A comparative study with captopril. Circulation 93:333-339
6. Gibbons GH, Pratt RE, Dzau VJ (1992) Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 90:456-461
7. Glaser R, Lu MM, Narula N, Epstein JA (2002) Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Circulation 106: 17-19
8. Gross CM, Gerbaulet S, Quensel C, Kramer J, Mittelmeier HO, Luft FC, Dietz R (2002) Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis. Basic Res Cardiol 97:327-333
9. Haznedaroglu IC, Ozturk MA (2003) Towards the understanding of the local hematopoietic bone marrow reninangiotensin system. Int J Biochem Cell Biol 35:867-880
10. Haznedaroglu IC, Tuncer S, Gursoy M (1996) A local renin-angiotensin system in the bone marrow. Med Hypotheses 46:507-510
11. Hillebrands JL, Klatter FA, van Den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J (2001) Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 107:1411-1422
12. Hirozane T, Matsumori A, Furukawa Y, Sasayama S (1995) Experimental graft coronary artery disease in a murine heterotopic cardiac transplant model. Circulation 91:386-392
13. Holtz J, Goetz RM (1994) Vascular reninangiotensin-system, endothelial function and atherosclerosis? Basic Res Cardiol 89(Suppl 1):71-86
14. Hope S, Brecher P, Chobanian AV (1999) Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens 12: 28-34
15. Koglin J, Glysing-Jensen T, Raisanen-Sokolowski A, Russell ME (1998) Immune sources of transforming growth factor-beta1 reduce transplant arteriosclerosis: Insight derived from a knockout mouse model. Circ Res 83:652-660
16. Nahmod KA, Vermeulen ME, Raiden S, Salamone G, Gamberale R, Fernandez-Calotti P, Alvarez A, Nahmod V, Giordano M, Geffner JR (2003) Control of dendritic cell differentiation by angiotensin II. Faseb J 17:491-493
17. Nickenig G, Bohm M (1998) Interaction between insulin and AT1 receptor. Relevance for hypertension and arteriosclerosis. Basic Res Cardiol 93 (Suppl 2):135-139
18. Oubina MP, de Las Heras N, Vazquez-Perez S, Cediel E, Sanz-Rosa D, Ruilope LM, Cachofeiro V, Lahera V (2002) Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens 20:303-310
19. Paul LC, Davidoff A, Benediktsson H (1994) Efficacy of cyclosporine and angiotensin-converting enzyme inhibitor to inhibit cardiac graft atherosclerosis in the rat. Transplant Proc 26:2873-2874
20. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906
21. Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B, Kajstura J, Leri A, Anversa P (2002) Chimerism of the transplanted heart. N Engl J Med 346: 5-15
22. Richter MH, Richter HR, Olbrich HG, Mohr FW (2003) Two good reasons for an angiotensin-II type 1 receptor blockade with losartan after cardiac transplantation: Reduction of incidence and severity of transplant vasculopathy. Transpl Int 16:26-32
23. Rodgers KE, Xiong S, Steer R, diZerega GS (2000) Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 18: 287-294
24. Russell ME, Adams DH, Wyner LR, Yamashita Y, Halnon NJ, Karnovsky MJ (1993) Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 90:6086-6090
25. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M (2001) Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 7:382-383
26. Saiura A, Sata M, Hirata Y, Nagai R, Makuuchi M (2001) Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation. Eur J Pharmacol 433:163-168
27. Sata M, Saiura A, Kunisato A, Tojo A, Okada S, Tokuhisa T, Hirai H, Makuuchi M, Hirata Y, Nagai R (2002) Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 8:403-409
28. Shimizu K, Sugiyama S, Aikawa M, Fukumoto Y, Rabkin E, Libby P, Mitchell RN (2001) Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 7:738-741
29. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM (2002) Smooth muscle progenitor cells in human blood. Circulation 106:1199-1204
30. Gross CM, Gerbaulet S, Quensel C, Kramer J, Mittelmeier HO, Luft FC, Dietz R (2002) Angiotensin II type 1 receptor expression in human coronary arteries with variable degrees of atherosclerosis. Basic Res Cardiol 97:327-333